A 2026 Cochrane systematic review of 17 trials involving 4,132 men found very weak evidence that bisphosphonates prevent fractures. Only 2 out of 1,000 men on bisphosphonates had hip fractures compared to 3 out of 1,000 on placebo, a difference too small to be certain about. These medications appear safe with no more side effects than placebo, but researchers say larger, longer studies are needed to determine if bone-strengthening drugs truly help men avoid fractures.
Researchers reviewed 17 studies involving over 4,100 men to see if medications commonly used to prevent broken bones actually work. According to Gram Research analysis, the evidence is surprisingly weak. Bisphosphonates, the most studied drugs, showed very little benefit in preventing hip fractures, spine fractures, or other breaks over two years. The good news: these medications appear safe and don’t cause more side effects than placebo. However, scientists say we need bigger, longer studies to know for sure whether these drugs truly help men avoid fractures. This review highlights an important gap: most bone health research focuses on women, leaving men’s treatment options unclear.
Key Statistics
A 2026 Cochrane systematic review of 17 randomized controlled trials involving 4,132 men found that bisphosphonates resulted in hip fractures in only 2 per 1,000 men compared to 3 per 1,000 on placebo, a difference too small to be statistically certain.
According to research reviewed by Gram, bisphosphonates probably do not increase the risk of adverse events in men, with 75% of men on the drug reporting side effects compared to 70% on placebo, a non-significant difference.
A 2026 systematic review found that spine fractures occurred in 4 per 1,000 men taking bisphosphonates versus 8 per 1,000 on placebo over two years, but researchers emphasized very low certainty in this finding due to study quality issues.
The 2026 Cochrane review identified only 17 eligible trials testing bone-strengthening medications in men aged 50 and older, highlighting a major research gap compared to the extensive evidence available for women.
The Quick Take
- What they studied: Whether medications that strengthen bones actually prevent fractures in men aged 50 and older.
- Who participated: 4,132 men with an average age between 52 and 73 years from 17 different clinical trials. Most studies lasted up to two years.
- Key finding: Bisphosphonates, the most common bone-strengthening drugs, showed very weak evidence of preventing fractures in men. Only 2 out of 1,000 men on the drug had hip fractures compared to 3 out of 1,000 on placebo, but this difference was too small to be certain.
- What it means for you: If you’re a man considering bone-strengthening medication, talk with your doctor about whether you truly need it. The current evidence doesn’t strongly support using these drugs for fracture prevention in men, though they appear safe. Larger studies are needed to give clearer answers.
The Research Details
This was a systematic review, which means researchers searched medical databases for all high-quality studies comparing bone-strengthening medications to placebo or other treatments in men. They found 17 randomized controlled trials, the gold standard for medical research, involving 4,132 men. Most studies compared bisphosphonates (the most common bone drugs) to placebo, while a few tested newer medications like denosumab and romosozumab. The researchers carefully evaluated each study for quality and combined the results using statistical methods to see if patterns emerged.
The main medications tested were bisphosphonates (drugs like alendronate that slow bone loss), PTH analogues (hormones that stimulate bone building), denosumab (an antibody that blocks bone loss), and romosozumab (a newer drug combining both approaches). Researchers looked at whether these drugs prevented hip fractures, spine fractures, and other breaks. They also tracked side effects and how many people quit the studies due to problems.
The studies ranged from comparing drugs to placebo to comparing different medications against each other. Most lasted up to two years, which is relatively short for bone health research. The researchers used strict criteria to decide which studies to include and assessed each one for potential bias or problems that might affect the results.
This research matters because osteoporosis, a condition where bones become weak and brittle, affects millions of men worldwide. However, most research on bone medications has focused on women, leaving doctors uncertain about what works best for men. By reviewing all available evidence on men specifically, this study provides the clearest picture we have of whether these expensive medications actually prevent fractures in the male population. Understanding the real benefits and risks helps men and their doctors make informed decisions about treatment.
The researchers found significant quality issues with the studies they reviewed. Most studies had a high risk of bias, meaning the way they reported results may have been influenced by what researchers expected to find. Very few fractures actually occurred in the studies, making it hard to draw firm conclusions. The studies were also relatively short (up to two years), but bone health changes often take longer to show up. The researchers downgraded their confidence in the findings multiple times due to these limitations, which is why they concluded the evidence is ‘very uncertain’ for most outcomes.
What the Results Show
For bisphosphonates compared to placebo, the results were underwhelming. Hip fractures occurred in only 2 out of 1,000 men taking bisphosphonates versus 3 out of 1,000 on placebo, a difference too small to be confident about. Spine fractures happened in 4 out of 1,000 men on bisphosphonates versus 8 out of 1,000 on placebo. Other fractures occurred in 16 out of 1,000 men on bisphosphonates versus 21 out of 1,000 on placebo. While these numbers suggest the drugs might help slightly, the researchers emphasized they cannot be certain because the differences are so small and the studies had quality problems.
The safety picture was clearer and more reassuring. About 75% of men taking bisphosphonates reported some side effect compared to 70% on placebo, a difference that was not statistically significant. Serious side effects occurred in about 27% of men on bisphosphonates versus 29% on placebo. Men taking bisphosphonates were actually less likely to quit the studies due to side effects (25 per 1,000) compared to placebo (37 per 1,000), suggesting these drugs are generally well-tolerated.
For newer medications like PTH analogues, denosumab, and romosozumab, the evidence was even more limited. Only a few studies tested these drugs in men, and the researchers concluded they are very uncertain about whether these medications prevent fractures. Denosumab and romosozumab appeared safe based on limited data, but fracture prevention benefits remain unclear.
The review found that no studies measured disability or quality of life in men taking these medications, which is an important gap. Researchers also noted that many studies didn’t clearly report all fractures that occurred, making it hard to know the true fracture rates. The comparison between different bisphosphonates and between bisphosphonates and other drugs provided very limited information due to small study sizes. One small study of 46 men suggested that bisphosphonate plus calcium might be better than calcium alone, but this finding came from too few participants to be reliable.
This review fills an important gap in bone health research. Most previous studies on bone-strengthening medications included mostly women, so doctors have had to guess whether results apply to men. This systematic review shows that the evidence for men is much weaker than what exists for women. In women, bisphosphonates have shown clearer benefits for preventing hip and spine fractures. The fact that men’s studies show such weak results suggests either that these drugs work differently in men, or that men with osteoporosis have different fracture patterns than women. This finding highlights why research specifically in men is essential.
The biggest limitation is that very few fractures actually occurred in these studies, making it hard to detect real differences between groups. Most studies lasted only up to two years, but bone health changes often take longer to develop. Many studies had quality problems, including unclear reporting of which fractures were counted. The studies were also relatively small, with some testing newer drugs in fewer than 300 men. Publication bias may exist, meaning studies showing negative results might not have been published. Finally, most participants were relatively healthy men without severe osteoporosis, so results may not apply to men with more advanced bone loss.
The Bottom Line
Current evidence does not strongly support using bisphosphonates or other bone-strengthening drugs to prevent fractures in men, though these medications appear safe. If you have significant bone loss or multiple fracture risk factors, discuss with your doctor whether medication is appropriate for you. Non-drug approaches like weight-bearing exercise, adequate calcium and vitamin D, and avoiding smoking remain important for all men. Confidence level: Low to moderate, based on weak evidence from short-term studies.
Men aged 50 and older considering bone-strengthening medications should pay attention to this research. Men with a history of fractures, family history of osteoporosis, or significant bone loss may still benefit from treatment, but the evidence is unclear. Men taking corticosteroid medications long-term should discuss bone health with their doctor. This research is less relevant for younger men or those with normal bone density. Healthcare providers treating male osteoporosis should be aware that evidence for medication benefits is weaker in men than in women.
If bone-strengthening medications do help prevent fractures in men, benefits would likely appear over 2 to 5 years based on how these drugs work. However, the current studies only tracked men for up to two years, which may be too short to see clear benefits. Most men would need to take these medications long-term to potentially see fracture prevention benefits. Results vary by individual based on age, bone density, and other health factors.
Frequently Asked Questions
Do bisphosphonates prevent fractures in men?
A 2026 systematic review found very weak evidence that bisphosphonates prevent fractures in men. Hip fractures occurred in only 2 per 1,000 men on bisphosphonates versus 3 per 1,000 on placebo. Researchers concluded the evidence is too uncertain to recommend these drugs for fracture prevention in men based on current studies.
Are bone-strengthening medications safe for men?
Yes, bisphosphonates appear safe in men. About 75% of men taking bisphosphonates reported side effects compared to 70% on placebo, a non-significant difference. Serious adverse events occurred in roughly 27% of men on bisphosphonates versus 29% on placebo, suggesting these drugs do not increase safety risks.
What should men do to prevent osteoporosis if medications don’t work?
Focus on proven lifestyle approaches: weight-bearing exercise like walking or strength training for 150 minutes weekly, adequate calcium intake (1,000-1,200 mg daily), vitamin D supplementation (600-800 IU daily), avoiding smoking, and limiting alcohol. These approaches have clearer evidence for bone health in men than medications.
Why is there less research on bone drugs in men than women?
Osteoporosis was historically considered a women’s disease, so most clinical trials focused on postmenopausal women. This 2026 review found only 17 trials in men versus hundreds in women, creating a significant evidence gap. Researchers now recognize men need their own studies since bone loss patterns differ between sexes.
Should I take bone medication if my doctor recommends it?
Discuss with your doctor whether your individual fracture risk justifies medication. Current evidence doesn’t strongly support routine use in men, but those with severe bone loss, multiple fractures, or corticosteroid use may still benefit. Your doctor can assess your personal risk factors to guide the decision.
Want to Apply This Research?
- Track bone health markers monthly: record any falls or minor injuries, monitor calcium and vitamin D intake (target 1,000-1,200 mg calcium and 600-800 IU vitamin D daily), and log weight-bearing exercise minutes (aim for 150 minutes weekly). If taking bone medication, note any side effects or concerns to discuss with your doctor.
- Start or increase weight-bearing exercise like walking, strength training, or dancing for at least 30 minutes most days. Ensure adequate calcium intake through food or supplements. Get vitamin D levels checked and supplement if needed. Avoid smoking and limit alcohol. These lifestyle changes have clearer evidence for bone health than medications in men.
- Set quarterly reminders to review bone health progress with your healthcare provider. Track any new aches, pains, or concerns related to bones and joints. Monitor medication adherence if prescribed. Schedule bone density scans as recommended by your doctor (typically every 1-2 years). Use the app to record conversations with your doctor about whether to continue, start, or stop bone medications based on your individual risk.
This article summarizes research findings and should not replace professional medical advice. Decisions about bone-strengthening medications should be made in consultation with your healthcare provider, who can assess your individual fracture risk, bone density, medical history, and other factors. The evidence reviewed here suggests current medications have limited proven benefit for fracture prevention in men, but individual circumstances vary. Do not start, stop, or change any medications without discussing with your doctor. If you have concerns about bone health or fracture risk, seek evaluation from a qualified healthcare professional.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.